Jagsonpal Pharmaceuticals Ltd Q3FY26 profit at Rs. 10.95 crores

has reported Standalone financial results for the period ended December 31, 2025.

Financial Results (Q3 FY2026) - QoQ Comparison

The company has reported total income of Rs. 75.920 crores during the period ended December 31, 2025 as compared to Rs. 77.492 crores during the period ended September 30, 2025.

The company has posted net profit / (loss) of Rs. 10.951 crores for the period ended December 31, 2025 as against net profit / (loss) of Rs. 12.574 crores for the period ended September 30, 2025.

The company has reported EPS of Rs. 1.65 for the period ended December 31, 2025 as compared to Rs. 1.87 for the period ended September 30, 2025.

Financials	Q3 FY2026	Q2 FY2026	% Change
Total Income	₹ 75.920 crs	₹77.492 crs	-2.03%
Net Profit	₹10.951 crs	₹12.574 crs	-12.91%
EPS	₹1.65	₹1.87	-11.76%

Financial Results (Q3 FY2026) - YoY Comparison

The company has reported total income of Rs. 75.920 crores during the period ended December 31, 2025 as compared to Rs.76.347 crores during the period ended December 31, 2024.

The company has posted net profit / (loss) of Rs.10.951 crores for the period ended December 31, 2025 as against net profit / (loss) of Rs.31.990 crores for the period ended December 31, 2024.

The company has reported EPS of Rs.1.65 for the period ended December 31, 2025 as compared to Rs.4.74 for the period ended December 31, 2024.

Financials	Q3 FY2026	Q3 FY2025	% Change
Total Income	₹ 75.920 crs	₹76.347 crs	-0.56%
Net Profit	₹10.951 crs	₹31.990 crs	-65.77%
EPS	₹1.65	₹4.74	-65.19%

Financial Results (9 Months Ended FY2026) - YoY Comparison

The company has reported total income of Rs.231.849 crores during the 9 Months period ended December 31, 2025 as compared to Rs.215.576 crores during the 9 Months period ended December 31, 2024.

The company has posted net profit / (loss) of Rs.34.320 crores for the 9 Months period ended December 31, 2025 as against net profit / (loss) of Rs.48.778 crores for the 9 Months period ended December 31, 2024.

The company has reported EPS of Rs.5.10 for the 9 Months period ended December 31, 2025 as compared to Rs.7.26 for the 9 Months period ended December 31, 2024.

Financials	9 Months Ended FY2026	9 Months Ended FY2025	% Change
Total Income	₹231.849 crs	₹215.576 crs	7.55%
Net Profit	₹34.320 crs	₹48.778 crs	-29.64%
EPS	₹5.10	₹7.26	-29.75%

Source : Equity Bulls

Keywords

JagsonpalPharmaceuticals Q3FY26 Q3FY2026 9MFY26 9MFY2026 ResultUpdate